BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yu J, Zhou Z, Tay-Sontheimer J, Levy RH, Ragueneau-Majlessi I. Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016. Drug Metab Dispos 2018;46:835-45. [PMID: 29572333 DOI: 10.1124/dmd.117.078691] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 12.8] [Reference Citation Analysis]
Number Citing Articles
1 Lu C, Di L. In vitro and in vivo methods to assess pharmacokinetic drug– drug interactions in drug discovery and development. Biopharm Drug Dispos 2020;41:3-31. [DOI: 10.1002/bdd.2212] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
2 Pelkonen O, Hakkola J, Hukkanen J, Turpeinen M. CYP-associated drug–drug interactions: A mission accomplished? Arch Toxicol 2020;94:3931-4. [DOI: 10.1007/s00204-020-02912-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Mcfeely SJ, Ritchie TK, Yu J, Nordmark A, Berglund EG, Levy RH, Ragueneau‐majlessi I. Inhibitors of Organic Anion‐Transporting Polypeptides 1B1 and 1B3: Clinical Relevance and Regulatory Perspective. The Journal of Clinical Pharmacology 2020;60:1087-98. [DOI: 10.1002/jcph.1604] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Benesic A, Jalal K, Gerbes AL. Acute Liver Failure During Pirfenidone Treatment Triggered by Co-Medication With Esomeprazole. Hepatology 2019;70:1869-71. [PMID: 31034631 DOI: 10.1002/hep.30684] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
5 Yadav J, Paragas E, Korzekwa K, Nagar S. Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions. Pharmacol Ther 2020;206:107449. [PMID: 31836452 DOI: 10.1016/j.pharmthera.2019.107449] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
6 Peng Y, Cheng Z, Xie F. Evaluation of Pharmacokinetic Drug-Drug Interactions: A Review of the Mechanisms, In Vitro and In Silico Approaches. Metabolites 2021;11:75. [PMID: 33513941 DOI: 10.3390/metabo11020075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Bennett D, Lanzarone N, Fossi A, Perillo F, De Vita E, Luzzi L, Paladini P, Bargagli E, Sestini P, Rottoli P. Pirfenidone in chronic lung allograft dysfunction: a single cohort study. Panminerva Med 2020;62. [DOI: 10.23736/s0031-0808.19.03840-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
8 Sudsakorn S, Bahadduri P, Fretland J, Lu C. 2020 FDA Drug-drug Interaction Guidance: A Comparison Analysis and Action Plan by Pharmaceutical Industrial Scientists. CDM 2020;21:403-26. [DOI: 10.2174/1389200221666200620210522] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
9 Okano T, Kobayashi T, Yasuma T, D'Alessandro-Gabazza CN, Toda M, Fujimoto H, Nakahara H, Okano Y, Takeshita A, Nishihama K, Saiki H, Tomaru A, Fridman D'Alessandro V, Ishida S, Sugimoto H, Takei Y, Gabazza EC. Low-Dose of Intrapulmonary Pirfenidone Improves Human Transforming Growth Factorβ1-Driven Lung Fibrosis. Front Pharmacol 2020;11:593620. [PMID: 33390975 DOI: 10.3389/fphar.2020.593620] [Reference Citation Analysis]
10 Minegishi G, Kazuki Y, Nitta SI, Miyajima A, Akita H, Kobayashi K. In vivo evaluation of intestinal human CYP3A inhibition by macrolide antibiotics in CYP3A-humanised mice. Xenobiotica 2021;51:764-70. [PMID: 34013847 DOI: 10.1080/00498254.2021.1921314] [Reference Citation Analysis]
11 Benesic A, Jalal K, Gerbes AL. Drug-Drug Combinations Can Enhance Toxicity as Shown by Monocyte-Derived Hepatocyte-like Cells From Patients With Idiosyncratic Drug-Induced Liver Injury. Toxicological Sciences 2019;171:296-302. [DOI: 10.1093/toxsci/kfz156] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
12 Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomström-Lundqvist C, Calkins H, Corrado D, Deftereos SG, Diller GP, Gomez-Doblas JJ, Gorenek B, Grace A, Ho SY, Kaski JC, Kuck KH, Lambiase PD, Sacher F, Sarquella-Brugada G, Suwalski P, Zaza A; ESC Scientific Document Group. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J 2020;41:655-720. [PMID: 31504425 DOI: 10.1093/eurheartj/ehz467] [Cited by in Crossref: 181] [Cited by in F6Publishing: 100] [Article Influence: 181.0] [Reference Citation Analysis]
13 Clerbaux LA, Paini A, Lumen A, Osman-Ponchet H, Worth AP, Fardel O. Membrane transporter data to support kinetically-informed chemical risk assessment using non-animal methods: Scientific and regulatory perspectives. Environ Int 2019;126:659-71. [PMID: 30856453 DOI: 10.1016/j.envint.2019.03.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
14 Desrivot J, Van Kaem T, Allamassey L, Helmer E. Effect of GLPG1205, a GPR84 Modulator, on CYP2C9, CYP2C19, and CYP1A2 Enzymes: In Vitro and Phase 1 Studies. Clin Pharmacol Drug Dev 2021;10:1007-17. [PMID: 33955686 DOI: 10.1002/cpdd.956] [Reference Citation Analysis]
15 Yu J, Petrie ID, Levy RH, Ragueneau-Majlessi I. Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017. Drug Metab Dispos 2019;47:135-44. [PMID: 30442649 DOI: 10.1124/dmd.118.084905] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 9.5] [Reference Citation Analysis]
16 Docci L, Parrott N, Krähenbühl S, Fowler S. Application of New Cellular and Microphysiological Systems to Drug Metabolism Optimization and Their Positioning Respective to In Silico Tools. SLAS Discov 2019;24:523-36. [PMID: 30817893 DOI: 10.1177/2472555219831407] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Zhou T, Arya V, Zhang L. Comparing Various In Vitro Prediction Methods to Assess the Potential of a Drug to Inhibit P-glycoprotein (P-gp) Transporter In Vivo. J Clin Pharmacol 2019;59:1049-60. [PMID: 30924955 DOI: 10.1002/jcph.1413] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Qian J, Li Y, Zhang X, Chen D, Han M, Xu T, Chen B, Hu G, Li J. Herbacetin Broadly Blocks the Activities of CYP450s by Different Inhibitory Mechanisms. Planta Med 2021. [PMID: 34116570 DOI: 10.1055/a-1502-7131] [Reference Citation Analysis]
19 Minegishi G, Kazuki Y, Yamasaki Y, Okuya F, Akita H, Oshimura M, Kobayashi K. Comparison of the hepatic metabolism of triazolam in wild-type andCyp3a-knockout mice for understanding CYP3A-mediated metabolism inCYP3A-humanised mice in vivo. Xenobiotica 2019;49:1303-10. [DOI: 10.1080/00498254.2018.1560516] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
20 Mistry P, Balwani M, Barbouth D, Burrow TA, Ginns EI, Goker-Alpan O, Grabowski GA, Kartha RV, Kishnani PS, Lau H, Lee CU, Lopez G, Maegawa G, Packman S, Prada C, Rosenbloom B, Lal TR, Schiffmann R, Weinreb N, Sidransky E. Gaucher disease and SARS-CoV-2 infection: Emerging management challenges. Mol Genet Metab 2020;130:164-9. [PMID: 32471800 DOI: 10.1016/j.ymgme.2020.05.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
21 Berman E, Eyal S. Drug Interactions in Space: a Cause for Concern? Pharm Res 2019;36:114. [PMID: 31152244 DOI: 10.1007/s11095-019-2649-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Tokuno M, Taguchi K, Sakai H, Ohtsuki S, Yamasaki K, Otagiri M. Assessing cytochrome P450-based drug-drug interactions with hemoglobin-vesicles, an artificial red blood cell preparation, in healthy rats. Drug Metab Pharmacokinet 2020;35:425-31. [PMID: 32788076 DOI: 10.1016/j.dmpk.2020.06.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Levy RH, Ragueneau‐majlessi I. Past, Present, and Future of Drug–Drug Interactions. Clin Pharmacol Ther 2019;105:1286-8. [DOI: 10.1002/cpt.1349] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
24 Yu J, Wang Y, Ragueneau-Majlessi I. Pharmacokinetic Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration in 2020: Mechanistic Understanding and Clinical Recommendations. Drug Metab Dispos 2022;50:1-7. [PMID: 34620694 DOI: 10.1124/dmd.121.000401] [Reference Citation Analysis]
25 Rousset-jablonski C, Reynaud Q, Perceval M, Nove-josserand R, Durupt S, Ray-coquard I, Golfier F, Durieu I. Improvement in contraceptive coverage and gynecological care of adult women with cystic fibrosis following the implementation of an on-site gynecological consultation. Contraception 2020;101:183-8. [DOI: 10.1016/j.contraception.2019.10.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 Choi YH. Interpretation of Drug Interaction Using Systemic and Local Tissue Exposure Changes. Pharmaceutics 2020;12:E417. [PMID: 32370191 DOI: 10.3390/pharmaceutics12050417] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
27 Sasabe H, Koga T, Furukawa M, Matsunaga M, Sasahara K, Hashizume K, Oozone Y, Amunom I, Torii M, Umehara K, Kashiyama E, Takeuchi K. In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole. Xenobiotica 2021;51:522-35. [PMID: 33663326 DOI: 10.1080/00498254.2021.1897898] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Safar Z, Kis E, Erdo F, Zolnerciks JK, Krajcsi P. ABCG2/BCRP: variants, transporter interaction profile of substrates and inhibitors. Expert Opin Drug Metab Toxicol 2019;15:313-28. [PMID: 30856014 DOI: 10.1080/17425255.2019.1591373] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
29 Smolej L, Vodárek P, Écsiová D, Šimkovič M. Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking? Cancers (Basel) 2021;13:3134. [PMID: 34201565 DOI: 10.3390/cancers13133134] [Reference Citation Analysis]
30 Li XQ, Thelingwani RS, Bertilsson L, Diczfalusy U, Andersson TB, Masimirembwa C. Evaluation of 1β-Hydroxylation of Deoxycholic Acid as a Non-Invasive Urinary Biomarker of CYP3A Activity in the Assessment of Inhibition-Based Drug-Drug Interaction in Healthy Volunteers. J Pers Med 2021;11:457. [PMID: 34073662 DOI: 10.3390/jpm11060457] [Reference Citation Analysis]
31 Lemaitre F, Solas C, Grégoire M, Lagarce L, Elens L, Polard E, Saint-Salvi B, Sommet A, Tod M, Barin-Le Guellec C; French Society of Pharmacology, Therapeutics (SFPT), the International Association of Therapeutic Drug Monitoring, Clinical Toxicology (IATDMCT). Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments. Fundam Clin Pharmacol 2020;34:530-47. [PMID: 32603486 DOI: 10.1111/fcp.12586] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
32 Bechtold B, Clarke J. Multi-factorial pharmacokinetic interactions: unraveling complexities in precision drug therapy. Expert Opin Drug Metab Toxicol 2021;17:397-412. [PMID: 33339463 DOI: 10.1080/17425255.2021.1867105] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 McFeely SJ, Ritchie TK, Yu J, Nordmark A, Levy RH, Ragueneau-Majlessi I. Identification and Evaluation of Clinical Substrates of Organic Anion Transporting Polypeptides 1B1 and 1B3. Clin Transl Sci 2019;12:379-87. [PMID: 30706983 DOI: 10.1111/cts.12623] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
34 Hall A, Chanteux H, Ménochet K, Ledecq M, Schulze MED. Designing Out PXR Activity on Drug Discovery Projects: A Review of Structure-Based Methods, Empirical and Computational Approaches. J Med Chem 2021;64:6413-522. [PMID: 34003642 DOI: 10.1021/acs.jmedchem.0c02245] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
35 Hakkola J, Hukkanen J, Turpeinen M, Pelkonen O. Inhibition and induction of CYP enzymes in humans: an update. Arch Toxicol 2020;94:3671-722. [PMID: 33111191 DOI: 10.1007/s00204-020-02936-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
36 Guo Z, Caro L, Robertson MN, Hwang P, Hoover P, Wudarski C, Maiuri K, Wang YH, Mogg R, Mehrotra DV, Blanchard R, Shaw PM. The pharmacogenetics of OATP1B1 variants and their impact on the pharmacokinetics and efficacy of elbasvir/grazoprevir. Pharmacogenomics 2019;20:631-41. [PMID: 31250727 DOI: 10.2217/pgs-2019-0022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Zhang L, Huang SM, Reynolds K, Madabushi R, Zineh I. Transporters in Drug Development: Scientific and Regulatory Considerations. Clin Pharmacol Ther 2018;104:793-6. [PMID: 30270426 DOI: 10.1002/cpt.1214] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
38 Burke A, Smith D, Coulter C, Bell SC, Thomson R, Roberts JA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis. Clin Pharmacokinet 2021. [PMID: 33982266 DOI: 10.1007/s40262-021-01010-4] [Reference Citation Analysis]
39 Ogawa S, Shimizu M, Kamiya Y, Uehara S, Suemizu H, Yamazaki H. Increased plasma concentrations of an antidyslipidemic drug pemafibrate co-administered with rifampicin or cyclosporine A in cynomolgus monkeys genotyped for the organic anion transporting polypeptide 1B1. Drug Metabolism and Pharmacokinetics 2020;35:354-60. [DOI: 10.1016/j.dmpk.2020.03.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
40 Lidberg KA, Annalora AJ, Jozic M, Elson DJ, Wang L, Bammler TK, Ramm S, Monteiro MB, Himmelfarb J, Marcus CB, Iversen PL, Kelly EJ. Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease. Sci Rep 2021;11:4722. [PMID: 33633318 DOI: 10.1038/s41598-021-84194-w] [Reference Citation Analysis]
41 Guengerich FP, McCarty KD, Chapman JG. Kinetics of cytochrome P450 3A4 inhibition by heterocyclic drugs defines a general sequential multistep binding process. J Biol Chem 2021;296:100223. [PMID: 33449875 DOI: 10.1074/jbc.RA120.016855] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Tokuno M, Taguchi K, Yamasaki K, Otagiri M. Hepatic Cytochrome P450 Profiles in Hemorrhagic Shock Model Rats After Transfusion With Stored Red Blood Cells. J Pharm Sci 2020;109:3490-5. [PMID: 32860801 DOI: 10.1016/j.xphs.2020.08.015] [Reference Citation Analysis]